首页 > 最新文献

Hepato-gastroenterology最新文献

英文 中文
Endoscopic excavation for the treatment of small esophageal subepithelial tumors originating from the muscularis propria. 内镜下挖掘治疗源自固有肌层的食管上皮下小肿瘤。
Pub Date : 2015-01-01
Li-ping Ye, Lin-hong Zhu, Xian-bin Zhou, Xin-li Mao, Yu Zhang

Background/aims: This study was designed to evaluate the safety and efficacy of endoscopic excavation for esophageal subepithelial tumors originating from the muscularis propria.

Methodology: Forty-five patients with esophageal subepithelial tumors originating from the muscularis propria were treated with endoscopic excavation between January 2010 and June 2012. The key steps were: (1) making several dots around the tumor; (2) incising the mucosa along with the marker dots, and then seperating the tumor from the muscularis propria by using a hook knife or an insulated-tip knife; (3) closing the artificial ulcer with clips after the tumor was removed.

Results: The mean tumor diameter was 1.1 ± 0.6 cm. Endoscopic excavation was successfully performed in 43 out of 45 cases (95.6%), the other 2 cases were ligated with nylon rope. During the procedure perforation occurred in 4 (8.9%) patients, who recovered after conservative treatment. No massive bleeding or delayed bleeding occurred. Histologic diagnosis was obtained from 43 (95.6%) patients. Pathological diagnoses of these tumors were leiomyomas (38/43) and gastrointestinal stromal tumors (5/43).

Conclusions: Endoscopic excavation is a safe and effective method for the treatment of small esophageal subepithelial tumors originating from the muscularis propria.

背景/目的:本研究旨在评价内镜下食管上皮下固有肌层肿瘤的安全性和有效性。方法:2010年1月至2012年6月对45例食道固有肌层上皮下肿瘤进行内镜下挖掘治疗。关键步骤是:(1)在肿瘤周围画几个点;(2)沿标记点切开粘膜,用钩刀或绝缘尖刀将肿瘤与固有肌层分离;(3)肿瘤切除后用夹子闭合人工溃疡。结果:肿瘤平均直径1.1±0.6 cm。45例中43例(95.6%)手术成功,2例用尼龙绳结扎。术中发生穿孔4例(8.9%),经保守治疗后恢复。无大出血或迟发性出血。43例(95.6%)患者获得组织学诊断。病理诊断为平滑肌瘤(38/43)和胃肠道间质瘤(5/43)。结论:内镜下切除是治疗源自固有肌层的食管上皮下小肿瘤的一种安全有效的方法。
{"title":"Endoscopic excavation for the treatment of small esophageal subepithelial tumors originating from the muscularis propria.","authors":"Li-ping Ye,&nbsp;Lin-hong Zhu,&nbsp;Xian-bin Zhou,&nbsp;Xin-li Mao,&nbsp;Yu Zhang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>This study was designed to evaluate the safety and efficacy of endoscopic excavation for esophageal subepithelial tumors originating from the muscularis propria.</p><p><strong>Methodology: </strong>Forty-five patients with esophageal subepithelial tumors originating from the muscularis propria were treated with endoscopic excavation between January 2010 and June 2012. The key steps were: (1) making several dots around the tumor; (2) incising the mucosa along with the marker dots, and then seperating the tumor from the muscularis propria by using a hook knife or an insulated-tip knife; (3) closing the artificial ulcer with clips after the tumor was removed.</p><p><strong>Results: </strong>The mean tumor diameter was 1.1 ± 0.6 cm. Endoscopic excavation was successfully performed in 43 out of 45 cases (95.6%), the other 2 cases were ligated with nylon rope. During the procedure perforation occurred in 4 (8.9%) patients, who recovered after conservative treatment. No massive bleeding or delayed bleeding occurred. Histologic diagnosis was obtained from 43 (95.6%) patients. Pathological diagnoses of these tumors were leiomyomas (38/43) and gastrointestinal stromal tumors (5/43).</p><p><strong>Conclusions: </strong>Endoscopic excavation is a safe and effective method for the treatment of small esophageal subepithelial tumors originating from the muscularis propria.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"65-8"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33251969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The value of single-incision laparoscopic surgery for colorectal cancer: a systematic literature review. 单切口腹腔镜手术治疗结直肠癌的价值:系统文献综述。
Pub Date : 2015-01-01
Cong-Chao Ma, Ping Li, Liu-Hua Wang, Zhao-Yun Xia, Sheng-Wen Wu, Shao-Jun Wang, Chun-Ming Lu

Background/aims: Recently, single-incision laparoscopic colectomy (SILC) for colorectal malignancy is rapidly becoming the central issue for explorers of minimally invasive surgery worldwide. The aim of this systematic review was to establish the safety and efficacy of SILC for colorectal malignancy when implemented by experienced surgeons.

Methodology: PubMed, WHO international trial register and Embase were searched for publications concerning SILC and MLC from 2000 to 2013, with the last search on September 10, 2013. Only pure single-incision laparoscopic colonic surgery for malignant disease was included. Primary outcomes were the early postoperative complication profiles of SILC. Secondary outcomes were duration of operation time, blood loss, lymph node yields, conversion rate, distal margin of the resected tumor, and duration of hospital stay.

Results: Eight studies involving 547 patients met the inclusion criteria. Compared with multiport laparoscopic colectomy (MLC), SILC has less postoperative complication and bleeding. The conversion, the median lymph node retrieval, proximal margin of the resected tumor and distal margin of the resected tumor for malignant disease achieved with SILC was acceptable. There was no significant reduction in length of hospital stay with SILC.

Conclusion: SILC is a technically reliable and realistic approach with short-term results similar to those obtained with the MLC procedure.

背景/目的:近年来,单切口腹腔镜结肠切除术(SILC)治疗结直肠恶性肿瘤正迅速成为世界范围内微创手术探索者的中心问题。本系统综述的目的是建立由经验丰富的外科医生实施SILC治疗结直肠恶性肿瘤的安全性和有效性。方法:检索PubMed、WHO international trial register和Embase,检索2000 - 2013年SILC和MLC相关文献,最后一次检索时间为2013年9月10日。仅包括恶性疾病的纯单切口腹腔镜结肠手术。主要结局是SILC术后早期并发症概况。次要结果为手术时间、出血量、淋巴结数量、转换率、切除肿瘤远端边缘和住院时间。结果:8项研究547例患者符合纳入标准。与多口腹腔镜结肠切除术(MLC)相比,SILC术后并发症和出血较少。对于恶性肿瘤,SILC的转换、正中淋巴结回收、切除肿瘤的近端边缘和远端边缘都是可以接受的。SILC患者的住院时间没有显著减少。结论:SILC是一种技术上可靠和现实的方法,其短期效果与MLC手术相似。
{"title":"The value of single-incision laparoscopic surgery for colorectal cancer: a systematic literature review.","authors":"Cong-Chao Ma, Ping Li, Liu-Hua Wang, Zhao-Yun Xia, Sheng-Wen Wu, Shao-Jun Wang, Chun-Ming Lu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Recently, single-incision laparoscopic colectomy (SILC) for colorectal malignancy is rapidly becoming the central issue for explorers of minimally invasive surgery worldwide. The aim of this systematic review was to establish the safety and efficacy of SILC for colorectal malignancy when implemented by experienced surgeons.</p><p><strong>Methodology: </strong>PubMed, WHO international trial register and Embase were searched for publications concerning SILC and MLC from 2000 to 2013, with the last search on September 10, 2013. Only pure single-incision laparoscopic colonic surgery for malignant disease was included. Primary outcomes were the early postoperative complication profiles of SILC. Secondary outcomes were duration of operation time, blood loss, lymph node yields, conversion rate, distal margin of the resected tumor, and duration of hospital stay.</p><p><strong>Results: </strong>Eight studies involving 547 patients met the inclusion criteria. Compared with multiport laparoscopic colectomy (MLC), SILC has less postoperative complication and bleeding. The conversion, the median lymph node retrieval, proximal margin of the resected tumor and distal margin of the resected tumor for malignant disease achieved with SILC was acceptable. There was no significant reduction in length of hospital stay with SILC.</p><p><strong>Conclusion: </strong>SILC is a technically reliable and realistic approach with short-term results similar to those obtained with the MLC procedure.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"45-50"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33249645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High intensity focused ultrasound ablation for patients with inoperable liver cancer. 高强度聚焦超声消融术治疗不能手术的肝癌。
Pub Date : 2015-01-01
Lianyu Chen, Kun Wang, Zhen Chen, Zhiqiang Meng, Hao Chen, Huifeng Gao, Peng Wang, Huili Zhu, Junhua Lin, Luming Liu

Background/aims: To analyses the feasibility and efficacy of high intensity focused ultrasound (HIFU) treatment in patients with inoperable liver cancer.

Methodology: 187 patients were treated with HIFU, of all these patients 116 cases were Primary Liver Cancer (PLC) and 71 cases were Metastatic Liver Cancer (MLC). According to some parameters, such as clinical symptoms, the basis of main organs functional tests, imaging examinations, and progression-free survival (PFS) time to assess the safety and efficacy of HIFU in the treatment of liver cancer.

Results: 55 patients (29.4%) achieved CR and 73 patients (39.0%) achieved PR, 32 patients (17.1%) had responses of SD, and 27 patients (14.4%) were PD, respectively. Response rates were 90.5% (32 CR + 6 PR/42) in left lobe cancer and 64.1% (22 CR + 62 PR/131) in right lobe cancer. The median PFS for those CR case was 7 months, of PLC was 8 months, of MLC was 5 months.

Conclusions: HIFU is effective and feasible in the treatment of liver cancer. It offer a significant noninvasive therapy for local treatment of liver cancer. For those right lobe liver cancers or with poor ultrasonic window, increasing treatment time or repeated treatment may improve the efficiency of HIFU ablation.

背景/目的:分析高强度聚焦超声(HIFU)治疗不能手术肝癌的可行性及疗效。方法:对187例患者行HIFU治疗,其中原发性肝癌116例,转移性肝癌71例。根据临床症状、主要脏器功能检查基础、影像学检查、无进展生存期(PFS)时间等参数评价HIFU治疗肝癌的安全性和有效性。结果:CR达到55例(29.4%),PR达到73例(39.0%),SD缓解32例(17.1%),PD缓解27例(14.4%)。左叶癌有效率为90.5% (32 CR + 6 PR/42),右叶癌有效率为64.1% (22 CR + 62 PR/131)。CR病例的中位PFS为7个月,PLC为8个月,MLC为5个月。结论:HIFU治疗肝癌是有效可行的。它为肝癌的局部治疗提供了一种重要的无创治疗方法。对于右叶肝癌或超声窗口差的患者,增加治疗时间或重复治疗可提高HIFU消融的效率。
{"title":"High intensity focused ultrasound ablation for patients with inoperable liver cancer.","authors":"Lianyu Chen,&nbsp;Kun Wang,&nbsp;Zhen Chen,&nbsp;Zhiqiang Meng,&nbsp;Hao Chen,&nbsp;Huifeng Gao,&nbsp;Peng Wang,&nbsp;Huili Zhu,&nbsp;Junhua Lin,&nbsp;Luming Liu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>To analyses the feasibility and efficacy of high intensity focused ultrasound (HIFU) treatment in patients with inoperable liver cancer.</p><p><strong>Methodology: </strong>187 patients were treated with HIFU, of all these patients 116 cases were Primary Liver Cancer (PLC) and 71 cases were Metastatic Liver Cancer (MLC). According to some parameters, such as clinical symptoms, the basis of main organs functional tests, imaging examinations, and progression-free survival (PFS) time to assess the safety and efficacy of HIFU in the treatment of liver cancer.</p><p><strong>Results: </strong>55 patients (29.4%) achieved CR and 73 patients (39.0%) achieved PR, 32 patients (17.1%) had responses of SD, and 27 patients (14.4%) were PD, respectively. Response rates were 90.5% (32 CR + 6 PR/42) in left lobe cancer and 64.1% (22 CR + 62 PR/131) in right lobe cancer. The median PFS for those CR case was 7 months, of PLC was 8 months, of MLC was 5 months.</p><p><strong>Conclusions: </strong>HIFU is effective and feasible in the treatment of liver cancer. It offer a significant noninvasive therapy for local treatment of liver cancer. For those right lobe liver cancers or with poor ultrasonic window, increasing treatment time or repeated treatment may improve the efficiency of HIFU ablation.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"140-3"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33130555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgery of upper GI gastrointestinal stromal tumors: our experience, prognostic analysis. 上消化道间质瘤的手术治疗:经验及预后分析。
Pub Date : 2015-01-01 DOI: 10.5754/HGE12819
Wisit Kasetsermwiriya, E. Nagai, Kohei Nakata, Y. Nagayoshi, S. Shimizu, Masao Tanaka
BACKGROUND/AIMS To review our treatment experience of gastrointestinal stromal tumors (GISTs) of the upper gastrointestinal tract and identify the prognostic factors that influence tumor recurrence. METHODOLOGY Data of 46 consecutive patients with upper GI GISTs who underwent surgery from 1988 to 2011 were reviewed. The overall and disease-free survival rates and influence of clinicopathologic variables on disease-free survival rate were evaluated. RESULTS The median age was 64 years (range, 20-86 years). R0 resections were performed in 43 (93.5%) patients. With a median follow-up time of 33 months (1-275 months), there were 5 (10.9%) recurrences and 2 mortalities in the high-risk group. The overall survival and recurrence-free survival rates at 5 years were 92.1% and 84.6%, respectively. Male gender, tumor size of >10 cm, high numbers of mitotic figures, R1 resection, high risk according to the Joensuu criteria, and a Ki-67 index of >10% were associated with a poor prognosis. CONCLUSIONS Surgical resection of low- and intermediate-risk GISTs has excellent results. High counts of mitotic figures, male gender, incomplete resection, large tumor size, and a high Ki-67 index are associated with a poor prognosis.
背景/目的回顾上胃肠道间质瘤的治疗经验,探讨影响肿瘤复发的预后因素。方法回顾性分析1988 ~ 2011年连续行手术治疗的46例上消化道gist患者的资料。评估总生存率和无病生存率以及临床病理变量对无病生存率的影响。结果患者中位年龄64岁(范围20 ~ 86岁)。43例(93.5%)患者行R0切除。中位随访时间为33个月(1 ~ 275个月),高危组复发5例(10.9%),死亡2例。5年总生存率和无复发生存率分别为92.1%和84.6%。男性、肿瘤大小为> ~ 10cm、有丝分裂象数量多、R1切除、Joensuu标准高风险、Ki-67指数>≥10%与预后不良相关。结论手术切除低、中危间质间质瘤效果良好。有丝分裂象数高、男性、切除不全、肿瘤大小大、Ki-67指数高与预后不良有关。
{"title":"Surgery of upper GI gastrointestinal stromal tumors: our experience, prognostic analysis.","authors":"Wisit Kasetsermwiriya, E. Nagai, Kohei Nakata, Y. Nagayoshi, S. Shimizu, Masao Tanaka","doi":"10.5754/HGE12819","DOIUrl":"https://doi.org/10.5754/HGE12819","url":null,"abstract":"BACKGROUND/AIMS To review our treatment experience of gastrointestinal stromal tumors (GISTs) of the upper gastrointestinal tract and identify the prognostic factors that influence tumor recurrence. METHODOLOGY Data of 46 consecutive patients with upper GI GISTs who underwent surgery from 1988 to 2011 were reviewed. The overall and disease-free survival rates and influence of clinicopathologic variables on disease-free survival rate were evaluated. RESULTS The median age was 64 years (range, 20-86 years). R0 resections were performed in 43 (93.5%) patients. With a median follow-up time of 33 months (1-275 months), there were 5 (10.9%) recurrences and 2 mortalities in the high-risk group. The overall survival and recurrence-free survival rates at 5 years were 92.1% and 84.6%, respectively. Male gender, tumor size of >10 cm, high numbers of mitotic figures, R1 resection, high risk according to the Joensuu criteria, and a Ki-67 index of >10% were associated with a poor prognosis. CONCLUSIONS Surgical resection of low- and intermediate-risk GISTs has excellent results. High counts of mitotic figures, male gender, incomplete resection, large tumor size, and a high Ki-67 index are associated with a poor prognosis.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"477 1","pages":"87-92"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71080227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS. 聚乙二醇干扰素α -2a (40 KD)和/或高剂量利巴韦林诱导治疗难以治疗的基因型1型CHC患者:来自PROGRESS的药代动力学和病毒动力学(PK/VK)评估
Pub Date : 2015-01-01
Peter N Morcos, Ruby Leong, James A Thommes, Jean DePamphilis, Joseph F Grippo, Barbara J Brennan

Background/aims: PROGRESS randomized chronic hepatitis C genotype 1 patients with a baseline viral load ≥400,000 IU/mL weighing ≥85 kg to regimens of 180 μg/week for 48 weeks or 360 μg/week for 12 weeks followed by 180 μg/week for 36 weeks peginterferon alfa-2a plus ribavirin. This analysis explored pharmacokinetics and early viral kinetics (VK) and evaluates differences between groups.

Methodology: Blood samples for pharmacokinetic and VK analyses were collected from 51 patients enrolled in the PROGRESS study.

Results: Mean peginterferon alfa-2a trough concentration at week 12 was 11.7±4.3 ng/mL for 180 μg and 23.4±11.3 ng/mL for 360 μg. Early VK profiles suggested a trend towards an enhanced viral decline in the 360 μg groups with a mean decrease in HCV RNA at 48 hours post first dose of 1.04 log10 (IU/mL) compared with 0.76 log10 (IU/mL) in the 180 μg groups. Mean beta slope increased with dose, ranging from 0.38±0.26 log10 IU/week at 180 μg to 0.52±0.32 log10 IU/week at 360 μg.

Conclusions: Early viral de clines may be enhanced with the 360 μg dose. These data may suggest the utility of high-dose peginterfer on alfa-2a plus direct-acting antivirals (DAA) in select difficult-to-treat populations.

背景/目的:将基线病毒载量≥400,000 IU/mL、体重≥85 kg的慢性丙型肝炎基因1型患者随机分组,给予180 μg/周治疗48周或360 μg/周治疗12周,随后给予180 μg/周治疗36周的聚乙二醇干扰素α -2a加利巴韦林治疗。该分析探讨了药代动力学和早期病毒动力学(VK),并评估了组间的差异。方法:从51名PROGRESS研究的患者中收集血液样本进行药代动力学和VK分析。结果:聚乙二醇干扰素α -2a第12周平均谷浓度为180 μg时为11.7±4.3 ng/mL, 360 μg时为23.4±11.3 ng/mL。早期VK谱显示360 μg组的病毒下降趋势增强,首次给药后48小时HCV RNA平均下降1.04 log10 (IU/mL),而180 μg组为0.76 log10 (IU/mL)。平均β斜率随剂量增加而增加,范围从180 μg时的0.38±0.26 log10 IU/周到360 μg时的0.52±0.32 log10 IU/周。结论:360 μg剂量可增强病毒的早期消退。这些数据可能表明,在选择难以治疗的人群中,高剂量聚乙二醇干扰素加直接作用抗病毒药物(DAA)的效用。
{"title":"Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS.","authors":"Peter N Morcos,&nbsp;Ruby Leong,&nbsp;James A Thommes,&nbsp;Jean DePamphilis,&nbsp;Joseph F Grippo,&nbsp;Barbara J Brennan","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>PROGRESS randomized chronic hepatitis C genotype 1 patients with a baseline viral load ≥400,000 IU/mL weighing ≥85 kg to regimens of 180 μg/week for 48 weeks or 360 μg/week for 12 weeks followed by 180 μg/week for 36 weeks peginterferon alfa-2a plus ribavirin. This analysis explored pharmacokinetics and early viral kinetics (VK) and evaluates differences between groups.</p><p><strong>Methodology: </strong>Blood samples for pharmacokinetic and VK analyses were collected from 51 patients enrolled in the PROGRESS study.</p><p><strong>Results: </strong>Mean peginterferon alfa-2a trough concentration at week 12 was 11.7±4.3 ng/mL for 180 μg and 23.4±11.3 ng/mL for 360 μg. Early VK profiles suggested a trend towards an enhanced viral decline in the 360 μg groups with a mean decrease in HCV RNA at 48 hours post first dose of 1.04 log10 (IU/mL) compared with 0.76 log10 (IU/mL) in the 180 μg groups. Mean beta slope increased with dose, ranging from 0.38±0.26 log10 IU/week at 180 μg to 0.52±0.32 log10 IU/week at 360 μg.</p><p><strong>Conclusions: </strong>Early viral de clines may be enhanced with the 360 μg dose. These data may suggest the utility of high-dose peginterfer on alfa-2a plus direct-acting antivirals (DAA) in select difficult-to-treat populations.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"11-8"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33249640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of using low-dose computed tomography to assess patency in gastrointestinal tracts with a patency capsule. 使用低剂量计算机断层扫描评估胃肠通畅胶囊的有效性。
Pub Date : 2015-01-01
Tomohiro Shirasawa, Shinichi Hashimoto, Kensaku Shimizu, Ryo Kawasato, Takayuki Yokota, Hiroaki Shibata, Hideko Onoda, Teppei Yonezawa, Takeshi Okamoto, Jun Nishikawa, Naofumi Matsunaga, Isao Sakaida

Background/aims: A patency capsule (PC) is used to safely perform capsule endoscopy. When the PC is not excreted within the defined time frame, radiography often cannot localize the PC. Computed tomography (CT) localizes a PC more definitively than radiography. We evaluated the localization of PCs using low-dose (LD)-CT.

Methodology: Forty-nine patients received a PC and 33 did not excrete the PC within the defined time frame and underwent radiography and LDCT with a 90% exposure reduction.

Results: LDCT localized the PC in 31 patients (93.9%), whereas radiography localized it in 7 (21.2%), indicating a significantly higher detection rate with LDCT (P<0.0001). PC retention in the small intestine was confirmed by LDCT in 4 patients. Retention was not observed during capsule endoscopy in the patients with confirmed patency of the gastrointestinal tract. In 21 patients who underwent LDCT with the conventional photographing area, the effective radiographic exposure dose associated with LDCT was 1.43±1.08 mSv. Conversely, in the 12 patients who underwent LDCT with a reduced photographing area, the effective dose was reduced to 0.62±0.27 mSv (P<0.05).

Conclusion: LDCT with a reduced exposure dose can definitively localize a PC. Therefore, this method may allow capsule endoscopy to be performed for more diseases.

背景/目的:使用通畅胶囊(PC)安全地进行胶囊内窥镜检查。当前列腺癌未在规定时间内排出时,放射照相通常不能确定前列腺癌的位置。计算机断层扫描(CT)比放射照相更明确地定位PC。我们使用低剂量(LD) ct评估pc的定位。方法:49名患者接受了PC, 33名患者没有在规定的时间内排出PC,并接受了x线摄影和LDCT检查,暴露量减少了90%。结果:LDCT对PC的定位31例(93.9%),而x线摄影对PC的定位7例(21.2%),LDCT的检出率明显高于PC(结论:低剂量LDCT可明确定位PC)。因此,该方法可使胶囊内窥镜检查应用于更多的疾病。
{"title":"Effectiveness of using low-dose computed tomography to assess patency in gastrointestinal tracts with a patency capsule.","authors":"Tomohiro Shirasawa,&nbsp;Shinichi Hashimoto,&nbsp;Kensaku Shimizu,&nbsp;Ryo Kawasato,&nbsp;Takayuki Yokota,&nbsp;Hiroaki Shibata,&nbsp;Hideko Onoda,&nbsp;Teppei Yonezawa,&nbsp;Takeshi Okamoto,&nbsp;Jun Nishikawa,&nbsp;Naofumi Matsunaga,&nbsp;Isao Sakaida","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>A patency capsule (PC) is used to safely perform capsule endoscopy. When the PC is not excreted within the defined time frame, radiography often cannot localize the PC. Computed tomography (CT) localizes a PC more definitively than radiography. We evaluated the localization of PCs using low-dose (LD)-CT.</p><p><strong>Methodology: </strong>Forty-nine patients received a PC and 33 did not excrete the PC within the defined time frame and underwent radiography and LDCT with a 90% exposure reduction.</p><p><strong>Results: </strong>LDCT localized the PC in 31 patients (93.9%), whereas radiography localized it in 7 (21.2%), indicating a significantly higher detection rate with LDCT (P<0.0001). PC retention in the small intestine was confirmed by LDCT in 4 patients. Retention was not observed during capsule endoscopy in the patients with confirmed patency of the gastrointestinal tract. In 21 patients who underwent LDCT with the conventional photographing area, the effective radiographic exposure dose associated with LDCT was 1.43±1.08 mSv. Conversely, in the 12 patients who underwent LDCT with a reduced photographing area, the effective dose was reduced to 0.62±0.27 mSv (P<0.05).</p><p><strong>Conclusion: </strong>LDCT with a reduced exposure dose can definitively localize a PC. Therefore, this method may allow capsule endoscopy to be performed for more diseases.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"240-4"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33251250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesh erosion causes small bowel obstruction: a rare complication of laparoscopic inguinal hernia repair: case description and review of literature. 腹腔镜腹股沟疝修补术中一种罕见的并发症——补片糜烂引起小肠梗阻:病例描述及文献复习。
Pub Date : 2015-01-01
Tong-min Xue, Li-de Tao, Jie Zhang, Pei-Jian Zhang

Transabdominal preperitoneal (TAPP) and total extraperitoneal (TEP) are the two types of laparoscopic repair of the inguinal hernia. The main advantages of laparoscopic repair, as compared to open repair, are a shorter hospital stay and a quicker recovery to normal activities. However, we cannot be overlooked or neglected the complication of laparoscopic inguinal hernia repair although it brings us lots of benefits. We report a case of small bowel obstruction caused by a displaced mesh used for the laparoscopic inguinal hernia repair and review of literature.

经腹腹膜前疝修补术(TAPP)和全腹膜外疝修补术(TEP)是腹腔镜下腹股沟疝修补术的两种类型。与开放式修复相比,腹腔镜修复的主要优点是住院时间更短,恢复正常活动更快。腹腔镜腹股沟疝修补术虽然给我们带来了很多好处,但我们也不能忽视或忽视其并发症。我们报告一例因腹腔镜腹股沟疝修补术中移位的补片引起的小肠梗阻,并复习文献。
{"title":"Mesh erosion causes small bowel obstruction: a rare complication of laparoscopic inguinal hernia repair: case description and review of literature.","authors":"Tong-min Xue,&nbsp;Li-de Tao,&nbsp;Jie Zhang,&nbsp;Pei-Jian Zhang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Transabdominal preperitoneal (TAPP) and total extraperitoneal (TEP) are the two types of laparoscopic repair of the inguinal hernia. The main advantages of laparoscopic repair, as compared to open repair, are a shorter hospital stay and a quicker recovery to normal activities. However, we cannot be overlooked or neglected the complication of laparoscopic inguinal hernia repair although it brings us lots of benefits. We report a case of small bowel obstruction caused by a displaced mesh used for the laparoscopic inguinal hernia repair and review of literature.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"55-8"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33251966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term outcomes after extrahepatic excision of congenital choladocal cysts: 30 years of experience at a single center. 先天性胆总管囊肿肝外切除后的长期预后:单一中心30年的经验。
Pub Date : 2015-01-01
Hideo Ohtsuka, Koji Fukase, Hiroshi Yoshida, Fuyuhiko Motoi, Hiroki Hayashi, Takanori Morikawa, Takaho Okada, Kei Nakagawa, Takeshi Naitoh, Yu Katayose, Michiaki Unno

Background/aims: Congenital choladocal cysts are generally treated by resection of the dilated extrahepatic biliary duct followed by hepaticojejunostomy, but it is associated with postoperative complications, including postoperative cholangitis, intrahepatic calculi, pancreatitis, and carcinogenesis, in the remnant bile duct. We investigated the most common long-term complications and identified the factors implicated in their development.

Methodology: We conducted a retrospective review and analysis of the long-term complications of 65 patients surgically treated for congenital choledochal cysts between 1978 and 2008 at one institute. The risk factors for intrahepatic calculi were identified based on the odds ratios of the implicated variables.

Results: Cholangitis with high fever or abdominal pain was reported in 14 patients (21.5%), intrahepatic calculi in 12 (18.5%), pancreatitis in 3 (4.6%), and cholangiocarcinoma in 3 (4.6%). Diagnosis with type IVa choledochal cysts was the most significant risk factor, followed by age ≥30 years at the time of treatment, and the presence of preoperative intrahepatic calculi.

Conclusions: While precise and thorough surgical treatment is necessary to prevent the long-term development of complications after surgical excision of congenital choledochal cysts, it must be accompanied by long-term postoperative follow-up, especially of elderly patients and those with type IVa cysts.

背景/目的:先天性胆总管囊肿的治疗方法通常是切除扩张的肝外胆管,然后进行肝空肠吻合术,但它与术后并发症有关,包括残余胆管的术后胆管炎、肝内结石、胰腺炎和癌变。我们调查了最常见的长期并发症,并确定了影响其发展的因素。方法:回顾性分析某研究所1978年至2008年间65例先天性胆总管囊肿手术治疗的远期并发症。根据相关变量的比值比确定肝内结石的危险因素。结果:胆管炎伴高热或腹痛14例(21.5%),肝内结石12例(18.5%),胰腺炎3例(4.6%),胆管癌3例(4.6%)。诊断为IVa型胆总管囊肿是最重要的危险因素,其次是治疗时年龄≥30岁和术前是否存在肝内结石。结论:精确、彻底的手术治疗是预防先天性胆总管囊肿手术切除后并发症长期发展的必要条件,但必须配合术后长期随访,尤其是老年患者和IVa型囊肿患者。
{"title":"Long-term outcomes after extrahepatic excision of congenital choladocal cysts: 30 years of experience at a single center.","authors":"Hideo Ohtsuka,&nbsp;Koji Fukase,&nbsp;Hiroshi Yoshida,&nbsp;Fuyuhiko Motoi,&nbsp;Hiroki Hayashi,&nbsp;Takanori Morikawa,&nbsp;Takaho Okada,&nbsp;Kei Nakagawa,&nbsp;Takeshi Naitoh,&nbsp;Yu Katayose,&nbsp;Michiaki Unno","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Congenital choladocal cysts are generally treated by resection of the dilated extrahepatic biliary duct followed by hepaticojejunostomy, but it is associated with postoperative complications, including postoperative cholangitis, intrahepatic calculi, pancreatitis, and carcinogenesis, in the remnant bile duct. We investigated the most common long-term complications and identified the factors implicated in their development.</p><p><strong>Methodology: </strong>We conducted a retrospective review and analysis of the long-term complications of 65 patients surgically treated for congenital choledochal cysts between 1978 and 2008 at one institute. The risk factors for intrahepatic calculi were identified based on the odds ratios of the implicated variables.</p><p><strong>Results: </strong>Cholangitis with high fever or abdominal pain was reported in 14 patients (21.5%), intrahepatic calculi in 12 (18.5%), pancreatitis in 3 (4.6%), and cholangiocarcinoma in 3 (4.6%). Diagnosis with type IVa choledochal cysts was the most significant risk factor, followed by age ≥30 years at the time of treatment, and the presence of preoperative intrahepatic calculi.</p><p><strong>Conclusions: </strong>While precise and thorough surgical treatment is necessary to prevent the long-term development of complications after surgical excision of congenital choledochal cysts, it must be accompanied by long-term postoperative follow-up, especially of elderly patients and those with type IVa cysts.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33124960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Totally laparoscopic right colectomy: technique description. 全腹腔镜右结肠切除术:技术描述。
Pub Date : 2015-01-01
Wenguang Liu, Jie Li, Ketao Jin, Qinghuan Liu

Background/aims: Total laparoscopic right colectomy (TLRC) with intracorporeal anastomosis is not widely performed as it requires adequate skills and competence in the use of mechanical linear staplers. Here we describe the technique of TLRC for resection for right colon cancer.

Methodology: We have performed TLRC in a patient for right colon cancer. Technique description of TLRC as well as short-term outcomes is reported.

Results: A TLRC for the right colon adenocarcinoma has been successfully performed in a male patient. The specimen included 11 lymph nodes, all of which were free of metastasis.

Conclusions: TLRC for right colon cancer was safe and feasible.

背景/目的:全腹腔镜右结肠切除术(TLRC)与体内吻合并没有被广泛应用,因为它需要足够的技能和能力来使用机械线性吻合器。在此,我们描述了TLRC在右结肠癌切除术中的应用。方法:我们对一例右结肠癌患者行TLRC。报道了TLRC的技术描述及近期疗效。结果:1例男性患者成功行右结肠腺癌TLRC。标本包括11个淋巴结,均无转移。结论:TLRC治疗右结肠癌是安全可行的。
{"title":"Totally laparoscopic right colectomy: technique description.","authors":"Wenguang Liu,&nbsp;Jie Li,&nbsp;Ketao Jin,&nbsp;Qinghuan Liu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Total laparoscopic right colectomy (TLRC) with intracorporeal anastomosis is not widely performed as it requires adequate skills and competence in the use of mechanical linear staplers. Here we describe the technique of TLRC for resection for right colon cancer.</p><p><strong>Methodology: </strong>We have performed TLRC in a patient for right colon cancer. Technique description of TLRC as well as short-term outcomes is reported.</p><p><strong>Results: </strong>A TLRC for the right colon adenocarcinoma has been successfully performed in a male patient. The specimen included 11 lymph nodes, all of which were free of metastasis.</p><p><strong>Conclusions: </strong>TLRC for right colon cancer was safe and feasible.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"51-4"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33249646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interferon-α combined with lamivudine versus lamivudine monotherapy for the emergence of YMDD mutations in chronic hepatitis B infection: a meta-analysis of randomized controlled trials. 干扰素-α联合拉米夫定与拉米夫定单药治疗慢性乙型肝炎感染中YMDD突变的出现:随机对照试验的荟萃分析
Pub Date : 2015-01-01
Ya-li Zhang, Jie Zhang, Li-yan Cui

Background/aims: Tyrosine-methionine-aspartate-aspartate (YMDD) mutations were the main limitation of lamivudine (LAM) for treating chronic hepatitis B (CHB). The aim of this study was to evaluate whether LAM combined with IFN-α offer advantage over lamivudine monotherapy for the occurrence of YMDD mutations in CHB using a meta-analysis.

Methodology: We searched electronic databases and calculated the odds ratios (OR) with their 95% confidence intervals (CI) and pooled the results.

Results: Our meta-analysis indicated that the difference of YMDD mutation rates between the combination therapy of IFN-α2b, IFN-α2a and Peg-IFN-α2a respectively plus LAM and LAM monotherapy (95% CI, 3.25-9.70, 95% CI, 5.77-17.51, 95% CI, 6.79-26.13, respectively). The rate of YMDD mutations in LAM monotherapy was increased when compared with combination and sequential combination group (95% CI, 6.79-22.16, and 95% CI, 2.69-7.75, respectively). The YMDD mutation rate in combination therapy was lower than that of LAM monotherapy in HBeAg positive patients (95% CI, 4.98-13.23).

Conclusions: Our present meta-analysis suggests that different types of IFN-a in combination with LAM can significantly reduce the rate of YMDD mutation compared to LAM monotherapy.

背景/目的:酪氨酸-蛋氨酸-天冬氨酸-天冬氨酸(YMDD)突变是拉米夫定治疗慢性乙型肝炎(CHB)的主要限制因素。本研究的目的是通过荟萃分析来评估LAM联合IFN-α是否比拉米夫定单药治疗CHB中YMDD突变的发生更有优势。方法:检索电子数据库,计算优势比(OR)及其95%置信区间(CI),并汇总结果。结果:我们的荟萃分析显示,IFN-α2b、IFN-α2a和Peg-IFN-α2a分别联合LAM和LAM单药治疗的YMDD突变率差异(95% CI, 3.25 ~ 9.70, 95% CI, 5.77 ~ 17.51, 95% CI, 6.79 ~ 26.13)。与联合用药组和序贯联合用药组相比,LAM单药组YMDD突变率升高(95% CI分别为6.79 ~ 22.16和2.69 ~ 7.75)。在HBeAg阳性患者中,联合治疗的YMDD突变率低于LAM单药治疗(95% CI, 4.98 ~ 13.23)。结论:我们目前的荟萃分析表明,与LAM单药治疗相比,不同类型的IFN-a联合LAM可显著降低YMDD突变率。
{"title":"Interferon-α combined with lamivudine versus lamivudine monotherapy for the emergence of YMDD mutations in chronic hepatitis B infection: a meta-analysis of randomized controlled trials.","authors":"Ya-li Zhang,&nbsp;Jie Zhang,&nbsp;Li-yan Cui","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Tyrosine-methionine-aspartate-aspartate (YMDD) mutations were the main limitation of lamivudine (LAM) for treating chronic hepatitis B (CHB). The aim of this study was to evaluate whether LAM combined with IFN-α offer advantage over lamivudine monotherapy for the occurrence of YMDD mutations in CHB using a meta-analysis.</p><p><strong>Methodology: </strong>We searched electronic databases and calculated the odds ratios (OR) with their 95% confidence intervals (CI) and pooled the results.</p><p><strong>Results: </strong>Our meta-analysis indicated that the difference of YMDD mutation rates between the combination therapy of IFN-α2b, IFN-α2a and Peg-IFN-α2a respectively plus LAM and LAM monotherapy (95% CI, 3.25-9.70, 95% CI, 5.77-17.51, 95% CI, 6.79-26.13, respectively). The rate of YMDD mutations in LAM monotherapy was increased when compared with combination and sequential combination group (95% CI, 6.79-22.16, and 95% CI, 2.69-7.75, respectively). The YMDD mutation rate in combination therapy was lower than that of LAM monotherapy in HBeAg positive patients (95% CI, 4.98-13.23).</p><p><strong>Conclusions: </strong>Our present meta-analysis suggests that different types of IFN-a in combination with LAM can significantly reduce the rate of YMDD mutation compared to LAM monotherapy.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"133-9"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33130554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hepato-gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1